About
Michael Rogers has served as a member of Akebia Therapeutics' Board of Directors since the completion of the merger with Keryx Biopharmaceuticals in December 2018, having chaired Keryx's board from 2017 until the merger. He has more than 30 years of financial experience and executive leadership in the biotechnology industry. He served as Chief Financial Officer of Apnimed, Inc. from November 2020 to April 2024, of Aerpio Pharmaceuticals from 2017 to 2019, and of Acorda Therapeutics from 2013 to 2016, and was Chief Financial Officer of Indevus Pharmaceuticals from 1999 to 2009. Earlier in his career he was an investment banker at Lehman Brothers and PaineWebber focused on life sciences companies.
Roles
Akebia Therapeutics, Inc.
Director (Class III) · Current role
2018–present
Apnimed, Inc.
Chief Financial Officer · Development-stage pharmaceutical company focused on obstructive sleep apnea; financial consultant April-October 2024.
2020-2024
Aerpio Pharmaceuticals, Inc.
Chief Financial Officer · Merged with Aadi BioScience, Inc.
2017-2019
Acorda Therapeutics, Inc.
Chief Financial Officer · Public biotechnology company developing therapies for neurological disorders.
2013-2016
Indevus Pharmaceuticals, Inc.
Chief Financial Officer · Served until the company's sale to Endo Pharmaceuticals.
1999-2009
External Roles
EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.)
Former board member
—
Coronado Biosciences, Inc.
Former board member
—
Aravive, Inc.
Former board member
—
Director Compensation
FY 2025
Fees earned or paid in cash
$70,000
Also at Akebia Therapeutics, Inc.